Turning Lemons into Lemonade After a Glioblastoma Diagnosis “Get your ice-cold lemonade!” These words reverberated through the air outside the Yale School of Medicine as Claire and Molly Lindenbach tried to garner sales for their “Lemon-Aid” Stand. The unusual sight attracted the attention of students and professionals working in the area. Only four months earlier, Claire and Molly’s dad, Brett, worked as a […] August 4, 2022
Guest Blog: My Dad’s Diagnosis Continues to Bring Our Family Together My father, Urbano, was the first in his family to come to the U.S. in the late ’70s from his hometown in Tequila, Mexico. From as far back as I can remember, he has always put family first. My childhood memories are focused around big family events because everything was a cause for celebration. The most […] July 20, 2022
Hankin Family Establishes Fund to Advance Glioblastoma Research The date July 20 holds a different meaning this year for the Hankin family. On a day when Jennifer and Stephanie should be celebrating their parents’ 47th wedding anniversary, the two sisters instead honor their mother’s legacy on Glioblastoma (GBM) Awareness Day. Cindy passed away from glioblastoma in 2016 at the age of 63. On […] July 20, 2022
New Brain Tumor Clinical Trials: January – June 2022 It can be hard to keep track of new clinical trial opportunities opening across the United States. There are many clinical trials actively enrolling patients, and this report provides a summary of the studies that have recently opened or started for primary brain tumor patients*. To learn more about each trial, and to contact the […] July 5, 2022
New Treatment Approved for Certain Glioma Patients On June 22, 2022, the U.S. Food and Drug Administration (FDA) granted accelerated approval to a new treatment combination that will now be available as an option for certain brain tumor patients. The FDA approved the combination of two oral drugs called dabrafenib (brand name: Tafinlar) and trametinib (brand name: Mekinist) for the treatment of advanced tumors […] June 28, 2022